Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments
Serum CEA is a stronger prognostic biomarker for LUAD patients treated with EGFR-TKIs while offering consistent monitoring capabilities in chemotherapy-treated patients. These findings highlight the differential clinical value of serum CEA in guiding therapeutic strategies and monitoring disease progression across treatment modalities.
Authors
- Yen‐Shou Kuo (ORCID: https://orcid.org/0000-0002-4948-5219)
- Ming‐Yi Zheng
- Yi‐Shing Shieh (ORCID: https://orcid.org/0000-0001-7000-091X)
- Yu‐Ting Chou (ORCID: https://orcid.org/0000-0001-9274-8603)
- Tsai‐Wang Huang
Institutions
- Tri-Service General Hospital (TW)
- National Tsing Hua University (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1002/cam4.71170
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Tri-Service General Hospital
- National Science and Technology Council